ReachRxResearch
Home
Research
Sign Up
Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study
Back to Research Hub
  1. Home
  2. Research Hub
  3. Efficacy and Safety of Risankizumab in P…

Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study

British Journal of Dermatology·September 26Open Access
DermatologyPractice changingPsoriasisPhase III Randomized Controlled TrialIL-12/23 InhibitorIL-23 InhibitorPediatricSkyriziStelaraRisankizumabUstekinumab

Summary

View source

What was studied

The OptIMMize-1 phase III study (NCT04435600) evaluated the efficacy and safety of risankizumab (an IL-23 inhibitor) vs. ustekinumab over 52 weeks in paediatric patients with moderate-to-severe psoriasis across 4 study parts, with Part 2 randomising patients 2:1 to risankizumab vs. ustekinumab.

Key findings

At week 16 in Part 2 (risankizumab n=54 vs. ustekinumab n=28), sPGA0/1 rates were 79.6% vs. 75.0%, PASI75 rates were 85.2% vs. 85.7%, PASI90 rates were 64.8% vs. 60.7%, and PASI100 rates were notably higher with risankizumab (40.7% vs. 17.9%); efficacy was maintained or improved at week 52, with a safety profile consistent with adult studies.

Study limitations

The study was open-label in three of four parts, limiting blinding; the comparator arm (ustekinumab) in Part 2 was relatively small (n=28); and no placebo-controlled comparison was included.

Clinical implications

Risankizumab appears effective and well tolerated in paediatric moderate-to-severe psoriasis, with meaningful skin clearance, itch, and quality-of-life improvements sustained to 52 weeks, supporting its use as an advanced therapy option in this population.

Caveats

  • Part 2 is the only randomised, controlled portion of the study; Parts 1, 3, and 4 are open-label single-arm designs, which limits the strength of comparative conclusions across the full trial
  • Patients were not stratified by age subgroup within 'paediatric,' so it is unclear how findings apply to younger children vs. adolescents specifically
  • The ustekinumab comparator arm in Part 2 was small (n=28), reducing the power to detect differences in most outcomes other than PASI100

Related Questions

Explore related topics

What biologic therapies are currently approved for moderate-to-severe psoriasis in children and adolescents?How does risankizumab compare to other IL-23 inhibitors like ixekizumab or secukinumab in paediatric psoriasis?What are the long-term safety considerations of IL-23 inhibitors in paediatric patients?

Publication Details

Year
2026
Journal
British Journal of Dermatology
Sample Size
n=137
Source
View article
Keep scrolling
More content below.
Up Next